Trial Profile
Phase IIb Study of the Efficacy of FLU-v, a Broad Spectrum Influenza Vaccine in an H1N1 Influenza Healthy Human Challenge Model
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Aug 2020
Price :
$35
*
At a glance
- Drugs FLU-v (Primary) ; Montanide ISA-51
- Indications Influenza virus infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors SEEK
- 10 Jan 2019 Primary endpoint has been met. (Incidence of MMID), according to a hVIVO media release.
- 10 Jan 2019 Results presented in a hVIVO media release.
- 06 Jun 2017 Status changed from recruiting to completed.